Enhancing patient care, guided by informed decisions

A suite of diagnostic tools engineered to empower pathologists in the interpretation and grading of prostate tissue biopsy cores to elevate diagnostic accuracy and transform patient care.

The three biomarkers and their cognate diagnostic reagents developed by Envision Sciences are Appl1 (EV1), Sortilin (EV2) and Syndecan-1 (EV3).  Their characteristics and diagnostic properties are the subject of several published cell biological and clinical studies, and patent applications.

See Publications for further information.

How it works

EV1 – Appl1 – is a multifunctional endocytic adaptor protein that localises to a specific subset of early endosomes and is highly expressed in all grades of prostate cancer. Appl1 is involving the Wnt signalling pathway, which has a critical role in prostate cancer pathogenesis and has been linked to disease progression and metastatic prostate cancer.

EV2 – Sortilin – belongs to the Vps10p sorting receptor family of proteins and controls the transport of cargo from the trans-Golgi network to endosomes, lysosomes, secretory granules and the plasma membrane. Sortilin has increased expression in well-formed (Gleason pattern 3) prostate cancer glands. It has a distinctive apical perinuclear punctate appearance in pattern 3 which wanes and becomes more diffuse in higher grade cancerous tissue.

Syndecan-1 – EV3 – also known as (CD138), is a transmembrane (type I) heparan sulfate proteoglycan which participates in cell proliferation, migration and cell-matrix interactions. In prostate cancer, Syndecan-1 is expressed in poorly formed glands (Gleason pattern 4) and higher-grade cancer morphologies, nests and cords of cells, most cribriform and IDCP. Syndecan-1 has a direct role in growth factor binding and cell migration, and its expression has been associated with biochemical recurrence after radical prostatectomy.

The novel Envision Sciences Immunohistochemistry biomarkers, when used in combination, allow the inclusion of grade-relevant protein expression and distribution information to the purely architectural information provided by Hematoxylin and eosin (H&E) staining alone. They have been developed to help resolve the subjectivity associated with pathological interpretation H&E-based prostate histology.

Product features: Envision’s Prostate Cancer Biomarkers

Introducing a Prostate Cancer Panel of IHC Biomarkers: Revolutionising disease progression analysis

Envision’s Prostate Cancer Panel of IHC Biomarkers a combination of EV1 (APPL1), EV2 (Sortilin), and EV3 (Syndecan-1), offers a novel approach to understanding disease progression. By leveraging this innovative panel of biomarkers, pathologists may achieve a higher level of grading concordance by unveiling distinct pathogenic features that can help reduce result variability and enhance patient treatment strategies.


  • Enhanced cellular insights – IHC Biomarkers underscore cellular changes with unparalleled clarity
  • Standardised grading and staging – Facilitates grading and staging standardisation, promoting consistency across diagnoses.
  • Improved cancer staging – Supports improved staging of prostate cancer, crucial for effective treatment planning
  • Objective grading – Increase objectivity and reduces subjectivity of grading, ensuring reliable assessments.
  • Supported CPT Codes per Core


  • Deeper Insights into Prostate Cancer – Provides detailed information on the level and activity of prostate cancer.
  • Revolutionised Diagnosis – Allows for the detection of subtle nuances in cancer behavior, leading to more accurate and informed diagnoses.
  • Informed Treatment Decisions – Aids clinicians in making personalised treatment decisions that are tailored to the individual needs of each patient.
  • Improved Patient Outcomes – Assists in tailoring treatments more precisely helps improve the overall outcomes and quality of care for patients dealing with prostate cancer.